Product Information
RESTASIS 0.05% EYE EMULSION is a brand product labeled by Allergan, Inc., priced at $10.3166 per EA under NDC 00023916360. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Dec 23, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the cyclosporine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.5 mg/mL
Manufacturer
Allergan, Inc.NDC
00023916360
Classification
Brand
Dosage Form
EMULSION
Route
OPHTHALMIC
Effective Date
8/19/2026
Active Ingredients
CYCLOSPORINEApproval Type
New Drug (NDA)
FDA Application
NDA050790FDA Approved
12/23/2002
TE Code
AB
On Market Since
4/1/2003
Pharmacological Classes
Price Statistics
The NADAC for RESTASIS 0.05% EYE EMULSION has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 115.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.3166 per EA |
|---|---|
| All-time high | $10.3396 (Mar 15, 2023) |
| All-time low | $4.7953 (Nov 28, 2013) |
| 52-week high | $10.3248 |
| 52-week low | $10.3166 |
| Median price | $9.3687 |
| Average price | $8.6421 |
| Largest weekly change | +9.9% (Jan 13, 2016) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RESTASIS 0.05% EYE EMULSION?
The current National Average Drug Acquisition Cost (NADAC) for RESTASIS 0.05% EYE EMULSION, manufactured by Allergan, Inc., is $10.3166 per EA (NDC 00023916360), effective Aug 19, 2026.
How has the price of RESTASIS 0.05% EYE EMULSION changed over time?
Over the history we have for it, the NADAC for RESTASIS 0.05% EYE EMULSION has risen 115.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RESTASIS 0.05% EYE EMULSION?
Since Nov 28, 2013, the NADAC for RESTASIS 0.05% EYE EMULSION has ranged from a low of $4.7953 (Nov 28, 2013) to a high of $10.3396 (Mar 15, 2023), with a median of $9.3687 per EA.
Are there cheaper alternatives to RESTASIS 0.05% EYE EMULSION?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CYCLOSPORINE 0.05% EYE EMULSION, is $0.9240 per EA — about 91% below RESTASIS 0.05% EYE EMULSION.
Who manufactures RESTASIS 0.05% EYE EMULSION?
RESTASIS 0.05% EYE EMULSION (NDC 00023916360) is labeled by Allergan, Inc., and CMS classifies it as a brand product.